Bicycle Therapeutics Gears Up for $200 Million Public Offering of American Depositary Shares and Non-Voting Ordinary Shares

Bicycle Therapeutics plc, a biotechnology company that has developed a differentiated class of therapeutics utilizing its groundbreaking Bicycle® technology, announced the pricing of an underwritten public offering of 9,411,766 ADSs at a rate of $21.25 each, totaling an impressive $200 million in gross proceeds.

To add to that, Bicycle has additionally granted the underwriters the opportunity to buy up to 1,411,764 additional ADSs within a 30-day timeframe. The offering is expected to close on or around July 17, 2023, provided all customary closing conditions are met.

Bicycle is thrilled to announce the launch of a new offering, which will provide the company with much-needed capital to further propel its proprietary pipeline and other R&D, as well as provide support to its wider corporate efforts. The results of the offering are certain to bring tremendous dividends to the company’s operations in the coming months and years.

Goldman Sachs & Co. LLC, Jefferies, and Leerink Partners have joined forces to serve as joint book-running managers of a major offering. With their combined experience and expertise, the group is sure to make this a successful endeavor.

Leave a Comment